Literature DB >> 30053214

Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study.

Neil Boudville1, David W Johnson2, Junhui Zhao3, Brian A Bieber3, Ronald L Pisoni3, Beth Piraino4, Judith Bernardini4, Sharon J Nessim5, Yasuhiko Ito6, Graham Woodrow7, Fiona Brown8, John Collins9, Talerngsak Kanjanabuch10, Cheuk-Chun Szeto11, Jeffrey Perl12.   

Abstract

BACKGROUND: Peritoneal dialysis (PD)-related infections lead to significant morbidity. The International Society for Peritoneal Dialysis (ISPD) guidelines for the prevention and treatment of PD-related infections are based on variable evidence. We describe practice patterns across facilities participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).
METHODS: PDOPPS, a prospective cohort study, enrolled nationally representative samples of PD patients in Australia/New Zealand (ANZ), Canada, Thailand, Japan, the UK and the USA. Data on PD-related infection prevention and treatment practices across facilities were obtained from a survey of medical directors'.
RESULTS: A total of 170 centers, caring for >11 000 patients, were included. The proportion of facilities reporting antibiotic administration at the time of PD catheter insertion was lowest in the USA (63%) and highest in Canada and the UK (100%). Exit-site antimicrobial prophylaxis was variably used across countries, with Japan (4%) and Thailand (28%) having the lowest proportions. Exit-site mupirocin was the predominant exit-site prophylactic strategy in ANZ (56%), Canada (50%) and the UK (47%), while exit-site aminoglycosides were more common in the USA (72%). Empiric Gram-positive peritonitis treatment with vancomycin was most common in the UK (88%) and USA (83%) compared with 10-45% elsewhere. Empiric Gram-negative peritonitis treatment with aminoglycoside therapy was highest in ANZ (72%) and the UK (77%) compared with 10-45% elsewhere.
CONCLUSIONS: Variation in PD-related infection prevention and treatment strategies exist across countries with limited uptake of ISPD guideline recommendations. Further work will aim to understand the impact these differences have on the wide variation in infection risk between facilities and other clinically relevant PD outcomes.
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  infection; peritoneal dialysis; peritonitis

Mesh:

Substances:

Year:  2019        PMID: 30053214      PMCID: PMC6887924          DOI: 10.1093/ndt/gfy204

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  37 in total

1.  Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis.

Authors:  Htay Htay; Yeoungjee Cho; Elaine M Pascoe; Darsy Darssan; Annie-Claire Nadeau-Fredette; Carmel Hawley; Philip A Clayton; Monique Borlace; Sunil V Badve; Kamal Sud; Neil Boudville; Stephen P McDonald; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-21       Impact factor: 8.237

2.  Prophylactic antibiotics in the insertion of Tenckhoff catheters.

Authors:  W C Lye; E J Lee; C C Tan
Journal:  Scand J Urol Nephrol       Date:  1992

Review 3.  ISPD Catheter-Related Infection Recommendations: 2017 Update.

Authors:  Cheuk-Chun Szeto; Philip Kam-Tao Li; David W Johnson; Judith Bernardini; Jie Dong; Ana E Figueiredo; Yasuhiko Ito; Rumeyza Kazancioglu; Thyago Moraes; Sadie Van Esch; Edwina A Brown
Journal:  Perit Dial Int       Date:  2017 Mar-Apr       Impact factor: 1.756

4.  Hospitalization in peritoneal dialysis patients.

Authors:  L Fried; S Abidi; J Bernardini; J R Johnston; B Piraino
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

5.  Neighborhood location, rurality, geography, and outcomes of peritoneal dialysis patients in the United States.

Authors:  Rajnish Mehrotra; Kenneth Story; Steven Guest; Michelle Fedunyszyn
Journal:  Perit Dial Int       Date:  2011-12-01       Impact factor: 1.756

6.  Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.

Authors:  Joanna R Ghali; Kym M Bannister; Fiona G Brown; Johan B Rosman; Kathryn J Wiggins; David W Johnson; Stephen P McDonald
Journal:  Perit Dial Int       Date:  2011-06-30       Impact factor: 1.756

7.  Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients.

Authors:  Rhianna Miles; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Johan B Rosman; Kathryn J Wiggins; Kym M Bannister; David W Johnson
Journal:  Kidney Int       Date:  2009-06-10       Impact factor: 10.612

8.  A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis.

Authors:  W K Lo; C Y Chan; S W Cheng; J F Poon; D T Chan; I K Cheng
Journal:  Am J Kidney Dis       Date:  1996-10       Impact factor: 8.860

9.  The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peritonitis in Peritoneal Dialysis Patients: The PROMPT Study.

Authors:  Kalindu Muthucumarana; Prue Howson; Doug Crawford; Sally Burrows; Ramyasuda Swaminathan; Ashley Irish
Journal:  Kidney Int Rep       Date:  2016-06-11

10.  Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients.

Authors:  Hsin-Hsu Wu; I-Jung Li; Cheng-Hao Weng; Cheng-Chia Lee; Yung-Chang Chen; Ming-Yang Chang; Ji-Tseng Fang; Cheng-Chieh Hung; Chih-Wei Yang; Ya-Chung Tian
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more
  12 in total

Review 1.  Peritoneal Dialysis-Associated Peritonitis.

Authors:  Cheuk-Chun Szeto; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-08       Impact factor: 8.237

2.  Factors Associated With Increased Hospital Length of Stay in Peritoneal Dialysis Patients With Peritonitis: A Need for Antimicrobial Stewardship?

Authors:  Taylor Morrisette; Robert B Canada; Danielle Padgett; Joanna Q Hudson
Journal:  Hosp Pharm       Date:  2018-12-07

Review 3.  Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis.

Authors:  Laura Sola; Nathan W Levin; David W Johnson; Roberto Pecoits-Filho; Harith M Aljubori; Yuqing Chen; Stefaan Claus; Allan Collins; Brett Cullis; John Feehally; Paul N Harden; Mohamed H Hassan; Fuad Ibhais; Kamyar Kalantar-Zadeh; Adeera Levin; Abdulkarim Saleh; Daneil Schneditz; Irma Tchokhonelidze; Rumeyza Turan Kazancioglu; Ahmed Twahir; Robert Walker; Anthony J O Were; Xueqing Yu; Fredric O Finkelstein
Journal:  Kidney Int Suppl (2011)       Date:  2020-02-19

4.  Predictors and outcomes of peritoneal dialysis-related infections due to filamentous molds (MycoPDICS).

Authors:  Talerngsak Kanjanabuch; Tanawin Nopsopon; Tanittha Chatsuwan; Sirirat Purisinsith; David W Johnson; Nibondh Udomsantisuk; Guttiga Halue; Pichet Lorvinitnun; Pongpratch Puapatanakul; Krit Pongpirul; Ussanee Poonvivatchaikarn; Sajja Tatiyanupanwong; Saowalak Chowpontong; Rutchanee Chieochanthanakij; Oranan Thamvichitkul; Worapot Treamtrakanpon; Wadsamon Saikong; Uraiwan Parinyasiri; Piyatida Chuengsaman; Phongsak Dandecha; Jeffrey Perl; Kriang Tungsanga; Somchai Eiam-Ong; Suchai Sritippayawan; Surasak Kantachuvesiri
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

5.  Multiparametric quantitative renal MRI in children and young adults: comparison between healthy individuals and patients with chronic kidney disease.

Authors:  Jonathan R Dillman; Stefanie W Benoit; Deep B Gandhi; Andrew T Trout; Jean A Tkach; Katherine VandenHeuvel; Prasad Devarajan
Journal:  Abdom Radiol (NY)       Date:  2022-03-02

6.  Optimizing Peritoneal Dialysis-Associated Peritonitis Prevention in the United States: From Standardized Peritoneal Dialysis-Associated Peritonitis Reporting and Beyond.

Authors:  Jeffrey Perl; Douglas S Fuller; Neil Boudville; Alan S Kliger; Douglas E Schaubel; Isaac Teitelbaum; Bradley A Warady; Alicia M Neu; Priti R Patel; Beth Piraino; Martin Schreiber; Ronald L Pisoni
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 8.237

Review 7.  Periprocedural Peritonitis Prophylaxis: A Summary of the Microbiology and the Role of Systemic Antimicrobials.

Authors:  Leon Hsueh; Susie L Hu; Ankur D Shah
Journal:  Kidney Dis (Basel)       Date:  2021-02-18

8.  Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol.

Authors:  Surapon Nochaiwong; Chidchanok Ruengorn; Kajohnsak Noppakun; Setthapon Panyathong; Phongsak Dandecha; Manish M Sood; Chalermpong Saenjum; Ratanaporn Awiphan; Sasithorn Sirilun; Pajaree Mongkhon; Wilaiwan Chongruksut; Kednapa Thavorn
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

9.  Association of Local Unit Sampling and Microbiology Laboratory Culture Practices With the Ability to Identify Causative Pathogens in Peritoneal Dialysis-Associated Peritonitis in Thailand.

Authors:  Talerngsak Kanjanabuch; Tanittha Chatsuwan; Nibondh Udomsantisuk; Tanawin Nopsopon; Pongpratch Puapatanakul; Guttiga Halue; Pichet Lorvinitnun; Kittisak Tangjittrong; Surapong Narenpitak; Chanchana Boonyakrai; Sajja Tatiyanupanwong; Rutchanee Chieochanthanakij; Worapot Treamtrakanpon; Uraiwan Parinyasiri; Niwat Lounseng; Phichit Songviriyavithaya; Suchai Sritippayawan; Somchai Eiam-Ong; Kriang Tungsanga; David W Johnson; Bruce Robinson; Jeffrey Perl
Journal:  Kidney Int Rep       Date:  2021-02-02

10.  Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study.

Authors:  Yanglin Hu; Li Xu; XiaoHui Wang; Xiaofei Qin; Sheng Wan; Qing Luo; Yanqiong Ding; Xiaofen Xiao; Fei Xiong
Journal:  Int Urol Nephrol       Date:  2021-06-19       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.